## Ina Kötter

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6827385/publications.pdf

Version: 2024-02-01

85	6,688	40	80
papers	citations	h-index	g-index
106	106	106	7117 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 2010, 69, 1809-1815.	0.9	1,017
2	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2490.	7.4	566
3	2018 update of the EULAR recommendations for the management of Behçet's syndrome. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213225.	0.9	442
4	Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica, 2010, 95, 284-292.	3.5	321
5	The use of interferon $\hat{l}_{\pm}$ in behçet disease: review of the literature. Seminars in Arthritis and Rheumatism, 2004, 33, 320-335.	3.4	222
6	Behçet's disease: Ocular effects and treatment. Progress in Retinal and Eye Research, 2008, 27, 111-136.	15.5	185
7	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 344-353.	6.4	182
8	Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212608.	0.9	181
9	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Research and Therapy, 2011, 13, R75.	3.5	170
10	Longâ€ŧerm remission after cessation of interferonâ€ἷ± treatment in patients with severe uveitis due to Behħet's disease. Arthritis and Rheumatism, 2010, 62, 2796-2805.	6.7	157
11	Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis and Rheumatism, 2011, 63, 840-849.	6.7	147
12	Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nature Genetics, 2013, 45, 319-324.	21.4	130
13	Anakinra in Patients with Treatment-Resistant Adult-Onset Still's Disease: Four Case Reports with Serial Cytokine Measurements and a Review of the Literature. Seminars in Arthritis and Rheumatism, 2007, 37, 189-197.	3.4	126
14	MRI Findings in Inflammatory Muscle Diseases and Their Noninflammatory Mimics. American Journal of Roentgenology, 2009, 192, 1708-1716.	2.2	122
15	Nucleosome, the Main Autoantigen in Systemic Lupus Erythematosus, Induces Direct Dendritic Cell Activation via a MyD88-Independent Pathway: Consequences on Inflammation. Journal of Immunology, 2005, 174, 3326-3334.	0.8	104
16	CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medicationsâ€"results of a retrospective analysis of 117 cases. Clinical Rheumatology, 2006, 25, 482-486.	2.2	104
17	Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of behçet disease: results of an open 4-center trial. Seminars in Arthritis and Rheumatism, 2004, 33, 311-319.	3.4	95
18	Clinical and Histopathological Features of Patients with Systemic Sclerosis Undergoing Endomyocardial Biopsy. PLoS ONE, 2015, 10, e0126707.	2.5	92

#	Article	IF	CITATIONS
19	INTERFERON ALFA-2A: A NEW TREATMENT OPTION FOR LONG LASTING REFRACTORY CYSTOID MACULAR EDEMA IN UVEITIS?. Retina, 2006, 26, 786-791.	1.7	91
20	Evolution of cost structures in rheumatoid arthritis over the past decade. Annals of the Rheumatic Diseases, 2015, 74, 738-745.	0.9	90
21	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. Rheumatology, 2018, 57, 2200-2212.	1.9	89
22	Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polychondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. Annals of the Rheumatic Diseases, 2006, 66, 202-207.	0.9	85
23	Monocyte-derived dendritic cells over-express CD86 in patients with systemic lupus erythematosus. Rheumatology, 2006, 45, 1087-1095.	1.9	84
24	TLR9 independent interferon $\hat{l}_{\pm}$ production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Annals of the Rheumatic Diseases, 2014, 73, 2199-2207.	0.9	83
25	Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 730-737.	0.9	82
26	Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrology Dialysis Transplantation, 2000, 15, 1367-1372.	0.7	79
27	Interventional MR Imaging for Injection of Sacroiliac Joints in Patients with Sacroiliitis. American Journal of Roentgenology, 2000, 175, 265-266.	2.2	75
28	Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Research and Therapy, 2013, 15, R64.	3.5	63
29	High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. Rheumatology International, 2014, 34, 227-234.	3.0	63
30	Gender-specific differences in Adamantiades–Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. Rheumatology, 2015, 54, 121-133.	1.9	63
31	Hearing loss in Muckleâ€Wells syndrome. Arthritis and Rheumatism, 2013, 65, 824-831.	6.7	59
32	Optimization of Autologous Stem Cell Transplantation for Systemic Sclerosis â€" A Single-center Longterm Experience in 26 Patients with Severe Organ Manifestations. Journal of Rheumatology, 2012, 39, 269-275.	2.0	58
33	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. Seminars in Arthritis and Rheumatism, 2019, 48, 752-762.	3.4	56
34	Mixed response to tocilizumab for ankylosing spondylitis. Annals of the Rheumatic Diseases, 2010, 69, 2217-2218.	0.9	54
35	NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment. Arthritis Research and Therapy, 2011, 13, R196.	3.5	51
36	The Role of Dynamic Contrast-Enhanced MRI in the Differential Diagnosis of Psoriatic and Rheumatoid Arthritis. American Journal of Roentgenology, 2010, 194, 715-720.	2.2	49

#	Article	IF	Citations
37	Risk factors for severe Muckleâ€Wells syndrome. Arthritis and Rheumatism, 2010, 62, 3783-3791.	6.7	46
38	Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. Journal of Rheumatology, 2016, 43, 66-74.	2.0	42
39	B Cells Contribute to Heterogeneity of IL-17 Producing Cells in Rheumatoid Arthritis and Healthy Controls. PLoS ONE, 2013, 8, e82580.	2.5	41
40	Magnetic resonance imaging findings in patients with systemic scleroderma and musculoskeletal symptoms. European Radiology, 2013, 23, 212-221.	4.5	40
41	MRI Findings in Psoriatic Arthritis of the Hands. American Journal of Roentgenology, 2010, 195, 1187-1193.	2.2	39
42	Beh $\tilde{\text{A}}$ Set's disease in patients of German and Turkish origin living in Germany: a comparative analysis. Journal of Rheumatology, 2004, 31, 133-9.	2.0	38
43	Both pain and EEG response to cold pressor stimulation occurs faster in fibromyalgia patients than in control subjects. Psychiatry Research, 2000, 97, 237-247.	3.3	33
44	Response Evaluation of Musculoskeletal Involvement in Patients With Deep Morphea Treated With Methotrexate and Prednisolone: A Combined MRI and Clinical Approach. American Journal of Roentgenology, 2013, 200, W376-W382.	2.2	33
45	Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations. Rheumatology, 2014, 53, 919-922.	1.9	33
46	Interferon therapy in rheumatic diseases: state-of-the-art 2010. Current Opinion in Rheumatology, 2010, 22, 278-283.	4.3	32
47	Efficacy and Safety of Rituximab Treatment in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: Results from a German Registry (GRAID). Journal of Rheumatology, 2012, 39, 2153-2156.	2.0	32
48	Human Recombinant Interferon-α2a (rhIFNα2a) for the Treatment of Behçet's Disease with Sight-Threatening Retinal Vasculitis. , 2003, 528, 521-523.		31
49	Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up. Rheumatology International, 2007, 27, 1031-1039.	3.0	31
50	Assessment of Synovitis in Erosive Osteoarthritis of the Hand using DCE-MRI and Comparison with that in its Major Mimic, the Psoriatic Arthritis. Academic Radiology, 2011, 18, 804-809.	2.5	30
51	Successful Treatment of Cutaneous Leishmaniasis Caused by Leishmania aethiopica with Liposomal Amphothericin B in an Immunocompromised Traveler Returning from Eritrea. American Journal of Tropical Medicine and Hygiene, 2011, 84, 692-694.	1.4	28
52	Efficacy of pulsed intravenous immunoglobulin therapy in mixed connective tissue disease. Journal of the American Academy of Dermatology, 2002, 46, 123-127.	1.2	24
53	Interstitial Granulomatous Dermatitis With Arthritis Responding to Tocilizumab. Archives of Dermatology, 2012, 148, 17.	1.4	23
54	Quantitative chest CT analysis in patients with systemic sclerosis before and after autologous stem cell transplantation: comparison of results with those of pulmonary function tests and clinical tests. Rheumatology, 2016, 55, 1763-1770.	1.9	23

#	Article	IF	CITATIONS
55	Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature. Rheumatology International, 2019, 39, 337-344.	3.0	23
56	Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid $\hat{A}$ deposition. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1060-1062.	1.9	22
57	Imaging of Primary and Secondary Inflammatory Diseases Involving Large and Medium-Sized Vessels and Their Potential Mimics: A Multitechnique Approach. American Journal of Roentgenology, 2010, 194, 848-856.	2.2	21
58	In Vivo Imaging of Cell Proliferation Enables the Detection of the Extent of Experimental Rheumatoid Arthritis by 3′-Deoxy-3′- <sup>18</sup> F-Fluorothymidine and Small-Animal PET. Journal of Nuclear Medicine, 2013, 54, 151-158.	5.0	21
59	Progressive familial hearing loss in Muckle-Wells syndrome. Acta Oto-Laryngologica, 2012, 132, 756-762.	0.9	19
60	Cocaine-induced ANCA-associated renal disease: a case-based review. Rheumatology International, 2019, 39, 2005-2014.	3.0	17
61	Selenium status in fibromyalgia. Toxicology Letters, 1998, 96-97, 177-180.	0.8	15
62	Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s. Lupus Science and Medicine, 2014, 1, e000059.	2.7	15
63	Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis. Rheumatology International, 2010, 30, 709-712.	3.0	14
64	Gastrointestinal involvement in granulomatosis with polyangiitis and microscopic polyangiitis: histological features and outcome. International Journal of Rheumatic Diseases, 2014, 17, 412-419.	1.9	14
65	Enteric-coated mycophenolate sodium for progressive systemic sclerosisâ€"a prospective open-label study with CT histography for monitoring of pulmonary fibrosis. Clinical Rheumatology, 2013, 32, 673-678.	2.2	13
66	Tocilizumab treatment for polyarteritis nodosa. Rheumatology, 2020, 59, e63-e65.	1.9	13
67	The Use of Interferon-α in Behçet's Disease — Review of the Literature and Possible Mechanisms of Action. , 2003, 528, 503-509.		12
68	Behçet's disease in HLA-B*51 negative Germans and Turks shows association with HLA-Bw4-80I. Arthritis Research and Therapy, 2014, 16, R116.	3.5	12
69	The virtual fishbowl: bringing back dynamic debates to medical conferences. Annals of the Rheumatic Diseases, 2021, 80, 675-676.	0.9	11
70	Analysis of anti–topoisomerase I antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation. Rheumatology, 2016, 56, kew319.	1.9	10
71	Magnetic resonance spin-labeling perfusion imaging of synovitis in inflammatory arthritis at 3.0ÂT. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2009, 22, 175-180.	2.0	9
72	Whole exome sequencing identifies rare protein-coding variants in Behçet's disease. Arthritis and Rheumatology, 2015, 68, n/a-n/a.	5.6	9

#	Article	IF	CITATIONS
73	Cholestatic Liver Disease after Rituximab and Adalimumab and the Possible Role of Cross-Reacting Antibodies to Fab 2 Fragments. PLoS ONE, 2013, 8, e78856.	2.5	6
74	Behçet's Disease in Patients of German and Turkish Origin — A Comparative Study. , 2003, 528, 53-58.		5
75	Disseminated Epitheloid Hemangioendothelioma Mimicking Symptoms of Systemic Vasculitis. Oncology Research and Treatment, 2005, 28, 429-432.	1.2	5
76	Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial. Blood, 2012, 120, 964-964.	1.4	5
77	Medical Management of Behçet's Syndrome. , 2010, , 317-338.		3
78	Significance of pulmonary involvement in systemic sclerosis (SSc) ${\bf \hat{a}}{\in}$ 'data from the German SSc-network. , 2018, , .		2
79	Comparability of European League Against Rheumatology-Recommended Pharmacological Treatments of Oral Ulcers Associated with Behçet's Disease: A Systematic Literature Review of Randomized Controlled Trials. Open Access Rheumatology: Research and Reviews, 2020, Volume 12, 323-335.	1.6	2
80	Chromatin-activated neutrophils represent a major source of interferon $\hat{A}$ . Annals of the Rheumatic Diseases, 2011, 70, A38-A39.	0.9	1
81	TLR9-independent and immune complex-independent interferon $\hat{l}_{\pm}$ production by neutrophils upon netosis in response to circulating chromatin. Annals of the Rheumatic Diseases, 2012, 71, A84.1-A84.	0.9	0
82	A2.1â€Activated Neutrophils are able to Efficiently Produce Interferon-α and Retain this Capability in Systemic Lupus Erythematosus and Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases, 2013, 72, A4.2-A4.	0.9	0
83	The challenging treatment of Behcet's disease. Expert Opinion on Orphan Drugs, 2015, 3, 1101-1110.	0.8	0
84	Diffusing capacity (DLCO) as a potential surrogate marker for scleroderma related lung disease–data from the german network for systemic sclerosis. , 2017, , .		0
85	Papulonodular tattoo lesions as a clinical sign of systemic sarcoidosis. Clinical Rheumatology, 2022, , 1.	2.2	O